FDA gives thumbs down to MDMA for now, demanding further research
The much-anticipated decision has rattled supporters of psychedelic therapies. The drugmaker says it will ask the agency to reconsider.
mdma therapy
Can MDMA still win FDA approval? Supporters rally as time runs out
With support from both sides in Congress, advocates are still fighting to get the psychedelic drug approved as a mental health treatment, despite its rejection by the FDA's advisory committee in June.
Trouble for ecstasy? What MDMA’s FDA setback could mean for psychedelics
Psychedelics researchers and investors are still reeling from last week’s no vote for MDMA by a panel of advisers to the FDA.
As the FDA evaluates ecstasy treatment for PTSD, questions mount about the evidence
Clinical trials of MDMA have been promising, but concerns have emerged about the quality of the research. A June hearing scheduled by the Food and Drug Administration is likely to address them.